Influence of the Preparation Method on the Physicochemical Properties of Tolbutamide/Cyclodextrin Binary Systems

REFERENCES

• Szejtli J. Cyclodextrin Technology. Kluwer Academic Publishers, DordrechtThe Netherlands 1988; 1–78
   Google Scholar
• Saenger W. Cyclodextrin Inclusion Compounds in Research and Laboratory. Angew. Chem., Int. Ed. Engl. 1980; 19: 344–362
   Web of Science ®Google Scholar
• Clarke R. J., Coates J. H., Lincoln S. T. Inclusion Complexes of the Cyclomalto-Oligosaccharides (Cyclodextrins). Advances in Carbohydrate Chemistry and Biochemistry, R. S. Tipson, D. Horton. Academic Press, New York 1988; 46: 205–249
   Google Scholar
• Ventura C. A., Tirendi S., Puglisi G., Bousquet E., Panza L. Improvement of Water Solubility and Dissolution Rate of Ursodeoxycholic Acid and Chenodeoxycholic by Complexation with Natural and Modified β-Cyclodextrins. Int. J. Pharm. 1997; 149: 1–13
   Web of Science ®Google Scholar
• Özdemir N., Ordu S. Improvement of Dissolution Properties of Furosemide by Complexation with β-Cyclodextrin. Drug Dev. Ind. Pharm. 1998; 24(1)19–25
   PubMed Web of Science ®Google Scholar
• Mura P., Faucci M. T., Parrina P. L., Furlanetto S., Pinzauti S. Influence of the Preparation Method on the Physicochemical Properties of Ketoprofen-Cyclodextrin Binary Systems. Int. J. Pharm. 1999; 179: 117–128
   PubMed Web of Science ®Google Scholar
• Loftsson T., Olafsdottir B. The Effect of 2-HP-β-Cyclodextrin on the Simultaneous Dissolution and Degradation of Chlorambucil. Int. J. Pharm. 1990; 66: 289–292
   Web of Science ®Google Scholar
• Antoniadou E., Bukton G., Michaeleas S. G., Loukas Y. L., Efentakis M. The Formation of an Inclusion Complex of Methocarbamol with Hydroxypropyl-β-Cyclodextrin: The Effect on Chemical Stability, Solubility and Dissolution Rate. Int. J. Pharm. 1997; 158: 233–239
   Web of Science ®Google Scholar
• Mielcarek J. Analytical Study of Photodegradation of Inclusion Complexes of Nimodipine with α-, γ-, metil-β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin. Drug Dev. Ind. Pharm. 1998; 24: 197–200
   PubMed Web of Science ®Google Scholar
• Vila-Jato J. L., Blanco J., Torres J. J. Biopharmaceutical Aspects of the Tolbutamide-β-Cyclodextrin Inclusion Compound. Farmaco 1988; 43: 37–45
   Google Scholar
• Soliman O. A.E., Kimura K., Hirayama F., Uekama K., El-Sabbagh H. M., El-Gawad A., Hashim F. M. Amorphous Spironolactone-Hydroxypropylated Cyclodextrin Complexes with Superior Dissolution and Oral Bioavailability. Int. J. Pharm. 1997; 149: 73–83
   Web of Science ®Google Scholar
• Dhanaraju M., Kumaran K. S., Baskaran T., Moorthy M. S.R. Enhancement of Bioavailability of Griseofulvin by Its Complexation with β-Cyclodextrin. Drug Dev. Ind. Pharm. 1998; 24: 583–587
   PubMed Web of Science ®Google Scholar
• Otero-Espinar F. J., Anguiano-Igea S., Blanco-Mendes J., Vila Jato J. L. Reduction in the Ulcerogenicity of Naproxen by Complexation with β-Cyclodextrin. Int. J. Pharm. 1991; 70: 35–41
   Web of Science ®Google Scholar
• Lin S., Wouessidjewe D., Poelman M., Duchêne D. Vivo Evaluation of Indomethacin/Cyclodextrin Complexes Gastrointestinal Tolerance and Dermal Anti-inflammatory Activity. Int. J. Pharm. 1994; 106: 63–67
   Web of Science ®Google Scholar
• Szejtli J., Bolla-Pusztai E., Kajtar M. The β-Cyclodextrin Inclusion Complex of Menadione (Vitamin K3). Pharmazie 1982; 37: 725–728
   Web of Science ®Google Scholar
• Miralles M. J., McGinity J. W., Martin A. Combined Water-Soluble Carriers for Coprecipitates of Tolbutamide. J. Pharm. Sci. 1982; 71: 302–304
   PubMed Web of Science ®Google Scholar
• Higuchi T., Connors K. A. Phase-Solubility Techniques. Adv. Anal. Chem. Instrum. 1965; 4: 117–212
   Google Scholar
• Connors K. A., Mollica J. A. Theoretical Analysis of Comparative Studies of Complex Formation. J. Pharm. Sci. 1966; 55: 772–780
   PubMed Web of Science ®Google Scholar
• Boostsma H. P.R., Frijlink H. W., Eissens A., Proost J. H., Van Doorne H., Lerk C. F. β-Cyclodextrin as an Excipient in Solid Oral Dosage Forms: In Vitro and In Vivo Evaluation of Spray-Dried Diazepam-β-Cyclodextrin Products. Int. J. Pharm. 1989; 51: 213–223
   Web of Science ®Google Scholar
• Frijlink H. W., Eissens A., Schoonen A. J.M., Lerk C. F. The Effects of Cyclodextrins on Drug Release from Fatty Suppository Bases. I. In Vitro Observations. Eur. J. Pharm. Biopharm. 1991; 37: 178–182
   Web of Science ®Google Scholar
• Chow D., Karara A. Characterization, Dissolution and Bioavailability in Rats of Ibuprofen-β-Cyclodextrin Complex System. Int. J. Pharm. 1986; 28: 95–101
   Web of Science ®Google Scholar
• Kedzierewicz F., Hoffman M., Maincent P. Comparison of Tolbutamide β-Cyclodextrin Inclusion Compounds and Solid Dispersions. Int. J. Pharm. 1990; 58: 221–227
   Web of Science ®Google Scholar
• Ismail S. Interaction of Anti-Convulsant Drugs with Alpha- and Beta-Cyclodextrins I. Methsumide. STP Pharm. Sci. 1991; 1: 321–325
   Google Scholar
• Benesi H. A., Hildebrand J. H. A Spectrometric Investigation of the Interaction of Iodine with Aromatic Hydrocarbons. J. Am. Chem. Soc. 1949; 71: 2703–2707
   Web of Science ®Google Scholar
• Szejtli J. Molecular Entrapment and Release Properties of Drugs by Cyclodextrins. Controlled Drug Bioavailability, V. F. Smolen, L. A. Ball. Wiley, New York 1985; 3: 365–420
   Google Scholar
• Cabral-Marques H. M., Hadgraft J., Kellaway I. W. Studies of Cyclodextrins Inclusion Complexes. I. The Salbutamol-Cyclodextrin Complex as Studied by Phase Solubility and DSC. Int. J. Pharm. 1990; 63: 259–266
   Web of Science ®Google Scholar
• Chauvet A. Etude Thermoanalytique et Liodisponibilité de Dispersions Solids du Tolbutamide. J. Therm. Anal. 1994; 41: 1253–1261
   Web of Science ®Google Scholar
• Hassan M. A., Suleiman M. S., Najib N. M. Improvement of the In Vitro Dissolution Characteristics of Famotidine by Inclusion in β-Cyclodextrin. Int. J. Pharm. 1990; 58: 19–24
   Web of Science ®Google Scholar
• Kim K., Frank M., Henderson N. Application of Differential Scanning Calorimetry to the Study of Solid Drug Dispersions. J. Pharm. Sci. 1985; 74: 283–289
   PubMed Web of Science ®Google Scholar
• Uekama K., Otagiri M. Cyclodextrins in Drug Carrier Systems. CRC Crit. Rev. Ther. Drug Carrier Sys. 1987; 3: 1–40
   PubMed Web of Science ®Google Scholar
• Kurozumi M., Nambu N., Nagai T. Inclusion Compounds of Non-steroidal Anti-inflammatory and Other Slightly Water Soluble Drugs with α- and β-Cyclodextrins in Powdered Form. Chem. Pharm. Bull. 1975; 23: 3062–3068
   PubMed Web of Science ®Google Scholar
• Goldberg A. H., Gribaldi M., Kanig J. L., Myersohn M. Increasing Dissolution Rates and Gastrointestinal Absorption of Drugs. IV: Chloramphenicol-Urea System. J. Pharm. Sci. 1966; 55: 1205–1211
   PubMed Web of Science ®Google Scholar
• Erden N., Celebi N. A Study of Inclusion Complex of Naproxen with β-Cyclodextrin. Int. J. Pharm. 1988; 48: 83–89
   Web of Science ®Google Scholar